Press Releases June 2, 2026 06:00 PM

Fortrea to Attend Jefferies Global Healthcare Conference

Fortrea to Participate in Jefferies Global Healthcare Conference with Executive Leadership

By Priya Menon
Share
Twitter Reddit Facebook LinkedIn
FTRE

Fortrea, a global contract research organization, announced that its CEO, CFO, and SVP of Investor Relations will participate in the Jefferies Global Healthcare Conference. The company provides comprehensive clinical development solutions, partnering with biopharmaceutical, biotechnology, medical device, and diagnostic companies worldwide.

Fortrea to Attend Jefferies Global Healthcare Conference
FTRE
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Fortrea's leadership is engaging with investors through a fireside chat at a prominent healthcare conference, which could increase investor awareness.
  • The company operates globally with expertise across more than 20 therapeutic areas and covers phases I-IV of clinical trial management.
  • Fortrea supports innovation in life sciences by offering clinical pharmacology and consulting services, leveraging three decades of industry experience.

DURHAM, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global contract research organization (“CRO”), today announced that that CEO Anshul Thakral, CFO Jill McConnell, and SVP of Investor Relations, Tracy Krumme will participate in the following conference:

Jefferies Global Healthcare Conference (NYC)
Date: Thursday, June 4, 2026
Time: 8:45 AM EDT
Format: Fireside Chat

To register for the live webcast, please click here. A replay will be available in the Events & Presentations section of Fortrea’s Investor Relations website. Investors interested in one-on-one or group meetings should contact their Jefferies representatives.

About Fortrea

Fortrea (Nasdaq: FTRE) is a leading global provider of clinical development solutions to the life sciences industry. We partner with emerging and large biopharmaceutical, biotechnology, medical device and diagnostic companies to drive healthcare innovation that accelerates life changing therapies to patients. Fortrea provides phase I-IV clinical trial management, clinical pharmacology and consulting services. Fortrea’s solutions leverage three decades of experience spanning more than 20 therapeutic areas, a passion for scientific rigor, exceptional insights and a strong investigator site network. Our talented and diverse team, operating across approximately 100 countries, is scaled to deliver focused, agile solutions to clients globally. Learn more about how Fortrea is streamlining drug development at Fortrea.com and follow us on LinkedIn, X and Bluesky.

Fortrea Contacts

Tracy Krumme (Investors) – 984-385-6707, [email protected]
Sue Zaranek (Media) – 919-943-5422, [email protected]
Kate Dillon (Media) – 646-818-9115, [email protected]


Risks

  • Market and investor interest may be limited if the presentation fails to disclose new strategic initiatives or growth drivers, which could affect stock momentum.
  • The CRO sector faces competition and regulatory uncertainties impacting clinical trial timelines and service demand.
  • Global operational challenges, such as regulatory changes or geopolitical issues, could impact Fortrea's service delivery and client contracts.

More from Press Releases

Real-World Evidence of Eversense 365 Presented at ADA Demonstrating Strong Performance and Patient Impact in Both Open and Closed Loop Systems Jun 6, 2026 All In FutureTech Alliance Provides Strategic Updates: Hainan AIFA Digital Industrial Park, Silicon Photonics Compute Center Planning, and Cross-Border Optical Network Integration Jun 6, 2026 Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress Jun 6, 2026 InterPrivate Investment Partners V, Inc. Announces Closing of $201.25 Million Initial Public Offering Jun 5, 2026 Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 5, 2026